Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06616974 · ClinicalTrials.gov registry record · Phase 2
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
A Phase 2 study of Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction, sponsored by Tectonic Therapeutic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06616974 is a Phase 2 study of Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Tectonic Therapeutic. The registered enrollment target is 180 participants, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06616974, a Phase 2 study of Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Tectonic Therapeutic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TX000045- Dose A
- DRUG TX000045- Dose B
Study Locations (20)
Arizona
- Phoenix - Phoenix
- Scottsdale - Scottsdale
California
- San Francisco - San Francisco
- Santa Rosa - Santa Rosa
Florida
- Jacksonville - Jacksonville
- Tampa - Tampa
Georgia
- Augusta - Augusta
- McDonough - McDonough
New York
- New York - New York
- New York - New York
Colorado
- Aurora - Aurora
Idaho
- Boise - Boise
Illinois
- Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2026-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06616974
The ClinicalTrials.gov registry entry for NCT06616974 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (71% lower). The listed sponsor is Tectonic Therapeutic, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06616974 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06616974 about?
NCT06616974 is a clinical study titled "A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)". TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
What is the current status of trial NCT06616974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-09-04. Estimated completion is 2026-11-20.
What conditions does trial NCT06616974 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT06616974?
The interventions under investigation include: Placebo (DRUG), TX000045- Dose A (DRUG), TX000045- Dose B (DRUG).
Who is sponsoring clinical trial NCT06616974?
This trial is sponsored by Tectonic Therapeutic, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06616974 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
RECRUITING · Phase 2
Explore more on PlainTrial
Pulmonary Hypertension
All registered trials for this condition
Heart Failure With Preserved Ejection Fraction
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.